14,520 Shares in Hims & Hers Health, Inc. (NYSE:HIMS) Bought by Securian Asset Management Inc.

Securian Asset Management Inc. purchased a new position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 14,520 shares of the company's stock, valued at approximately $429,000.

A number of other institutional investors also recently made changes to their positions in HIMS. Victory Capital Management Inc. lifted its holdings in shares of Hims & Hers Health by 1.9% in the 4th quarter. Victory Capital Management Inc. now owns 52,579 shares of the company's stock worth $1,271,000 after purchasing an additional 1,002 shares during the last quarter. PNC Financial Services Group Inc. lifted its stake in shares of Hims & Hers Health by 51.9% in the fourth quarter. PNC Financial Services Group Inc. now owns 17,225 shares of the company's stock worth $417,000 after buying an additional 5,885 shares during the last quarter. Amundi lifted its position in Hims & Hers Health by 49.1% in the fourth quarter. Amundi now owns 12,741 shares of the company's stock worth $328,000 after purchasing an additional 4,197 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Hims & Hers Health by 16.6% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,450 shares of the company's stock worth $785,000 after purchasing an additional 4,620 shares during the last quarter. Finally, Avantax Advisory Services Inc. boosted its position in shares of Hims & Hers Health by 113.3% during the fourth quarter. Avantax Advisory Services Inc. now owns 26,456 shares of the company's stock worth $640,000 after purchasing an additional 14,053 shares in the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Trading Down 3.5%

Shares of NYSE:HIMS opened at $50.03 on Friday. The company has a fifty day simple moving average of $53.86 and a 200 day simple moving average of $41.62. The firm has a market cap of $11.20 billion, a PE ratio of 72.51, a price-to-earnings-growth ratio of 1.91 and a beta of 2.02. Hims & Hers Health, Inc. has a 12-month low of $13.47 and a 12-month high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.08. The firm had revenue of $586.01 million for the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a return on equity of 22.75% and a net margin of 9.24%. The firm's revenue for the quarter was up 110.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.05 EPS. As a group, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Activity at Hims & Hers Health

In other news, insider Soleil Boughton sold 2,572 shares of the business's stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $47.82, for a total value of $122,993.04. Following the transaction, the insider directly owned 158,165 shares of the company's stock, valued at $7,563,450.30. The trade was a 1.60% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Andrew Dudum sold 65,110 shares of the stock in a transaction that occurred on Tuesday, June 17th. The shares were sold at an average price of $59.22, for a total transaction of $3,855,814.20. Following the completion of the transaction, the chief executive officer owned 95,105 shares in the company, valued at $5,632,118.10. This represents a 40.64% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 633,126 shares of company stock worth $33,717,663 in the last three months. Company insiders own 13.71% of the company's stock.

Analyst Upgrades and Downgrades

HIMS has been the subject of several analyst reports. UBS Group set a $30.00 price target on shares of Hims & Hers Health in a research note on Monday, June 23rd. Piper Sandler reissued a "neutral" rating and issued a $39.00 price target (up from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Needham & Company LLC reissued a "hold" rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Wall Street Zen downgraded Hims & Hers Health from a "buy" rating to a "hold" rating in a research report on Saturday, July 12th. Finally, Morgan Stanley restated an "equal weight" rating and set a $40.00 price target on shares of Hims & Hers Health in a research report on Wednesday, June 11th. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $39.83.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.